Assessment of the Safety and Efficacy of the Dermal Filler "mARG-01-17" in Facial Rejuvenation Therapy

Facial Rejuvenation Clinical Trial

Official title:

An Open-Label Uncontrolled Single Center Study for the Evaluation of the Efficacy and Safety of the Dermal Filler "mARG-01-17" in the Facial Rejuvenation Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04643977
• Other study ID #: MD/mARG-06-04-2018
• Status: Completed
• Phase: N/A
• Start date: August 30, 2018
• Est. completion date: December 18, 2018

Study information

• Verified date: November 2020
• Source: Mesoestetic Pharma Group S.L.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the clinical investigation is to evaluate the performance of the mARG-01-17 dermal filler in the context of its efficacy and safety.

Description:

The study is an open-label uncontrolled single-center study for the evaluation of the Performance (efficacy and safety) of the dermal filler "mARG-01-17" in the facial rejuvenation therapy. The design is of a not blinded, not randomized, single group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 18, 2018
• Est. primary completion date: December 18, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female subjects;
• Age between =35 and =65 years;
• Subjects with WSRS (Wrinkle Severity Ranking Scale) score between 2 and 3;
• Skin phototype I - VI;
• Subjects with Glogau score between I and III;
• Subjects with either chrono and photoaging wrinkles, wrinkles of expression (Line of expression); Dry and dehydrated skin;
• Subjects who are willing to abstain from any cosmetic or surgical procedures (including botox injection) in the treatment area during the clinical investigation;
• Clinically and anamnestically healthy individual, especially absence of diseases that could interfere with the cutaneous aging evaluation;
• Absence of a history of significant hypersensitivity to food and drugs or known sensitivity to hyaluronic acid;
• Subjects without significant body weight fluctuation;
• Non-smoker and smokers;
• Arterial blood pressure (BP) (after 5 min. at rest in the supine position) systolic 90
• 140 mmHg and diastolic 50 - 90 mmHg;
• Heart rate (HR) (after 5 min. at rest in the supine position) over 50 beats/min and less than 90 beats/min;
• Respiratory rate between 12 - 24 breaths/min;
• Axillar body temperature of up to 370?;
• Clinical-laboratory examinations within the reference ranges or with no clinically significant abnormalities;
• Negative AIDS/HIV test;
• Negative pregnancy test for the women with reproductive potential;
• Reliable and acceptable method of contraception for the women of child-bearing potential;
• Signed written Informed Consent Form.

Exclusion Criteria:

• Subjects who had previously received permanent implants on the treated area;
• Subjects who underwent facial surgery or were injected with dermal fillers in the facial area within the previous 6 months before enrollment;
• Subjects who underwent facial procedures such as laser therapy, chemical peeling, dermo-abrasive treatments, or botulinum toxin injection within 12 months before enrollment;
• Subjects who indicate signs of dermatological problems, such as cutaneous lesions, acne and/or other inflammatory diseases in active phase, hypertrophic scars or a tendency to keloid formation;
• Subjects suffering from systemic diseases or alterations, such as diabetes mellitus, connective tissue diseases, uncontrolled systemic diseases;
• Subjects, suffering from or who have history of immune system disorders, such as autoimmune diseases, HIV positive status, history of immune system degradation or recurrent herpes simplex or who are undergoing treatment with immunosuppressors or immunotherapy;
• Subjects with known allergy or hypersensitivity to salicylic acid or its derivatives, any of the components of the product or cosmetic fillers to hyaluronic acid;
• Pregnant women;
• Breastfeeding women;
• Absence of a reliable and effective method of contraception;
• Subjects who are currently receiving another investigational treatment or who had participated in another clinical investigation within 30 days prior to study enrollment;
• Subjects who suffer from another medical condition or who are receiving medication that in the Principal Investigator's judgment would prohibit inclusion in the study;
• Subjects with limited mental activity and consistent comprehension ability; sportsmen and individuals on strenuous physical loading; prisoners;
• Refusal to sign the Informed Consent Form.

Related Conditions & MeSH terms

• Facial Rejuvenation
• Facies

Intervention

Device:
• mARG-01-17 (mesohyal AGRIBENONE)
Dermal Filler

Locations

Country	Name	City	State
Bulgaria	"Medical Center Asklepii" OOD	Dupnitsa

Sponsors (1)

Lead Sponsor	Collaborator
Mesoestetic Pharma Group S.L.

Country where clinical trial is conducted

Bulgaria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The absolute change in Global Aesthetic Improvement Scale (GAIS)	A 5-point scale rating global aesthetic improvement in appearance, compared to pre-treatment, as judged by the Principal Investigator. Grade 1 - Exceptional improvement, grade 5 - Worsened.	Between Day 0 to Day 90 (up to 12 weeks)
Primary	Safety endpoint	The frequency and severity of adverse events (AEs)	Between Day 0 to Day 90
Secondary	The absolute change in Global Aesthetic Improvement Scale (GAIS)	A 5-point scale rating global aesthetic improvement in appearance, compared to pre-treatment, as judged by the Principal Investigator. Grade 1 - Exceptional improvement, grade 5 - Worsened.	Between Day 0 and Days 15, 30, 45, 60 (up to 2, 4, 6 and 8 weeks respectively)
Secondary	The change in Wrinkle Severity Ranking Scale (WSRS)	A validated five-point reference scale with photographs for evaluation of the skin condition that classifies deep facial wrinkles, like the nasolabial folds. as judged by the Principal Investigator.Grade 1 - the Best result, grade 5 - being the worst result.	Between Day 0 and Days 15, 30, 45, 60 and 90 (up to 2, 4, 6, 8 and 12 weeks respectively)
Secondary	Subject satisfaction	A subject questionnaire including 5 point scale to evaluate the participant's satisfaction - 1 being very much improved and 5 - worsened.	Days 15, 30, 45, 60 and 90 (up to 2, 4, 6, 8 and 12 weeks respectively)